Net debt/EBITDA hit 28.1x as $514m of debt falls due within 12 months

Net debt / EBITDA reached 28.1x against a four-period mean of 8.9x and prior range of 5.7x–13.6x, with $514.0m of the $589.8m gross borrowings classified as repayable within 12 months. This sits alongside an operating collapse: EBITDA margin of 3.0% is below the prior range of 4.5%–8.7%, also classified as unprecedented.

Revenue fell 15.2% to $652.9m, the weakest reading in the supplied five-period window (range -15.2% to +40.4%). PBT swung from $6.1m to -$94.9m (n/m and NPAT from $4.8m to -$96.2m (n/m, of which a disclosed -$26.2m relates to discontinued operations; continuing-operations NPAT was -$70.0m. Total equity contracted 14.2% to $698.9m.

With $514.0m current and total gross borrowings up 11.4% to $589.8m, the company is operating under a balance-sheet review and an explicit deleveraging plan, including a stated intent to consider divestments. Lenders remain supportive per disclosure, but the gap between current EBITDA run-rate and current debt service load is what makes leverage at 28.1x economically meaningful rather than just a denominator effect.

Operating economics, not one-offs, are the bigger problem. Even excluding the -$26.2m discontinued-operations loss, continuing-operations NPAT was still -$70.0m. The Ingredients segment — 36.9% of revenue — generated only $1.4m of result on $293.0m of sales (a derived 0.5% margin), so segment mix is doing little to support consolidated profitability while Advanced Nutrition (14.3% derived margin) and Consumer (10.0%) absorb fixed costs.

Tax distortion widens the headline gap but does not change the read. The PBT-to-NPAT growth gap of 444.1pp reflects an effective tax rate of 26.3% (above the historical range of -35.9% to 24.7%) plus the discontinued-operations loss; PBT growth of n/m is the cleaner operating measure and is itself classified as unprecedented low.

The historical shape data shows HY23 was 58.3% of FY23 revenue and HY23 NPAT was -112.1% of FY23 NPAT, so a like-for-like seasonality read for the current half is unreliable. Annualised current revenue of $1.3b would sit roughly in line with FY23's $1.3b of continuing-operations revenue, but that assumes no further demand attrition.

What the release does support is direction, not magnitude: a strategy refresh, a refreshed executive team, narrowed balance-sheet options, and a multi-month strategic review whose outcome is explicitly uncertain. The gap matters because the timing of any divestment or recapitalisation is the binding variable on the 12-month debt classification.

OCF / EBITDA of -493.1% sits at the lower edge of the supplied four-period range. Inventories fell 32.4% to $316.3m, releasing roughly $151.5m of operating working capital — that release is what narrowed the cash outflow. Inventory days at 88.2 are within the historical range of 68.9–123.7 days, so the working-capital position has normalised rather than gone abnormally tight, which limits any further inventory-driven cash benefit in the second half. Pre-lease free cash flow of -$114.8m is within the supplied historical range (-$195.0m to +$71.2m).

Capex was cut 39.2% to $16.7m (2.6% of revenue versus 3.6% prior). FCF / NPAT of 119.3% is mathematically a function of two negatives and should not be read as cash strength. On balance, the cash improvement is balance-sheet-assisted rather than operational, which matters because it cannot be repeated at the same scale next half.

This briefing cannot assess covenant headroom, the probability of a successful divestment, or any post-balance-date refinancing developments, because those are not contained in the supplied disclosures.